spacer
home > ict > autumn 2016 > changing face
PUBLICATIONS
International Clinical Trials

Changing Face

The investigational study of pharmaceutical and biotechnology products is rapidly becoming a global endeavour. While the development of drugs has necessitated material supply such as active pharmaceutical ingredients, and with drug manufacture gradually moving from traditional developed countries like the US or European member states to emerging ones such as China and India, we are now witness to a geographic shift for the implementation of these trials.

International Range


In past years, a multi-country study might have involved only the US and developed European countries. This would require multi-language labelling and contending with the multitude of country-specific regulatory requirements, but would be limited to a handful of countries with advanced healthcare infrastructures to support the needs of a trial.

In today’s market, investigational studies are spreading to many emerging markets – including Russia, Ukraine, Eastern Bloc countries, Latin American countries such as Brazil and Argentina, as well as Central America. There is also a rise in conducting trials in the Asia-Pacific region, with significant population growth and rapidly developing healthcare infrastructure in dense urban areas.

It is, therefore, appealing to carry out investigational drug studies in the Asia-Pacific region, but this does come with risks and challenges depending on the location of the trial sites and the laws governing the country where the study is to be administered. For example, the regulatory requirements in Japan can vary significantly to those in regional neighbours like China, Malaysia, the Philippines, Taiwan, Singapore, South Korea and others. Every country needs to be evaluated independently for its attractiveness and its relative regulatory and logistical risk, as each is distinctly unique.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Rich Nelson is the Distribution Services Manager for PCI’s Clinical Services group, working with clients to provide seamless global distribution of their investigational products. Rich joined PCI in 2012 after seven years with Fisher Clinical Services, having supported both global distribution of investigational products as well as interactive voice response system solutions. He is certified in Lean Six Sigma/continuous improvement, and is a graduate of Monmouth University in West Long Branch, New Jersey.
spacer
Rich Nelson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility

Philadelphia, PA – June 4, 2019 PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement